Preterax reduces the likelihood of new or worsening nephropathy in patients with type 2 diabetes mellitus and can lead to nepropathy regression in those with existing kidney damage, research shows.
New results of the ADVANCE (Action in Diabetes and Vascular disease:PreterAx and DiamicroN-MR Controlled Evaluation) trial were presented yesterday at the European Society of Hypertension (ESH).
In this new ADVANCE analysis, Preterax reduces the risk of developing new onset microalbuminuria by 21% and macroalbuminuria by 31% and regresses renal disease by improving existing microalbuminuria or macroalbuminuria at baseline by 16% compared with placebo.
Furthermore, restoration of normoalbuminuria is improved by 15% in patients treated with Preterax.
Preterax’s renoprotective benefits were independent of concomitant treatments with other antihypertensives, initial blood pressure or duration of diabetes or glycaemic control.
ADVANCE is the largest study performed in patients with type 2 diabetes.